Amarin Corporation PLC (NASDAQ:AMRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $4.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 15.27% from the stock’s current price.

According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “

A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Tuesday, August 29th. BidaskClub downgraded Amarin Corporation PLC from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Jefferies Group LLC initiated coverage on Amarin Corporation PLC in a research report on Thursday, June 29th. They set a “reduce” rating and a $3.50 price target on the stock. ValuEngine raised Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $7.20.

Amarin Corporation PLC (NASDAQ AMRN) traded down 0.57% during midday trading on Tuesday, reaching $3.47. The company’s stock had a trading volume of 823,054 shares. Amarin Corporation PLC has a 1-year low of $2.65 and a 1-year high of $4.47. The company’s market capitalization is $939.65 million. The company has a 50 day moving average of $3.24 and a 200-day moving average of $3.32.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $40.35 million. The company’s revenue for the quarter was up 37.0% compared to the same quarter last year. During the same period last year, the business earned ($0.07) earnings per share. Equities research analysts anticipate that Amarin Corporation PLC will post ($0.21) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Amarin Corporation PLC (AMRN) Stock Rating Upgraded by Zacks Investment Research” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/03/amarin-corporation-plc-amrn-stock-rating-upgraded-by-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its stake in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 7,580 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Private Advisor Group LLC boosted its holdings in Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 1,032 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its holdings in Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 7,000 shares during the last quarter. 37.76% of the stock is currently owned by institutional investors and hedge funds.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get a free copy of the Zacks research report on Amarin Corporation PLC (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.